Barclays Maintains Overweight on Eli Lilly, Raises Price Target to $590
Portfolio Pulse from Benzinga Newsdesk
Barclays analyst Carter Gould maintains an Overweight rating on Eli Lilly (NYSE:LLY) and raises the price target from $500 to $590.
August 09, 2023 | 4:08 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Barclays maintains an Overweight rating on Eli Lilly and raises the price target from $500 to $590, indicating a positive outlook for the company.
The raised price target by Barclays indicates a positive outlook for Eli Lilly. This could lead to increased investor confidence and potentially a rise in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100